SIGLEC10-AS1

Across TCGA pan-cancer cohorts, SIGLEC10-AS1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SIGLEC10-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SIGLEC10-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SIGLEC10-AS1 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

KIRC, STAD, and LIHC are the cancer types where SIGLEC10-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SIGLEC10-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.108	<.001	8	view →
STAD	All	All	+0.226	<.001	6	view →
LIHC	All	II,III,IV	+0.055	<.001	6	view →
KIRP	Female	All	+0.104	.004	5	view →
UCEC	All	II,III,IV	+0.115	.031	4	view →
HNSC	All	All	+0.047	.006	4	view →
CHOL	All	All	+0.264	.007	2	view →
LUAD	Male	All	−0.129	.009	2	view →
KICH	Male	II,III,IV	+0.113	.025	1	view →
THCA	All	IV	+0.060	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

SIGLEC10-AS1–KIRC

Open the KIRC breakdown →